FdaApplication
NDA 021121
Identifiers
- fda_app_no: NDA021121
Properties
| Property | Value |
|---|---|
| applicant_name | JANSSEN PHARMACEUTICALS INC |
| application_type | NDA |
| approval_date | 2000-08-01 |
Revenue by product
CONCERTA
| Period | Revenue |
|---|---|
| Q2 2026 | $146.0M |
| Q1 2026 | $136.0M |
| Q4 2025 | $132.0M |
| Q3 2025 | $140.0M |
| Q2 2025 | $164.0M |
| Q1 2025 | $148.0M |
| Q4 2024 | $159.0M |
| Q3 2024 | $142.0M |
| Q2 2024 | $163.0M |
| Q1 2024 | $177.0M |
| Q4 2023 | $180.0M |
| Q3 2023 | $189.0M |
| Q2 2023 | $208.0M |
| Q1 2023 | $206.0M |
| Q4 2022 | $168.0M |
| Q3 2022 | $158.0M |
| Q2 2022 | $161.0M |
| Q1 2022 | $157.0M |
| Q4 2021 | $178.0M |
| Q3 2021 | $157.0M |
| Q2 2021 | $161.0M |
| Q1 2021 | $171.0M |
| Q4 2020 | $153.0M |
| Q3 2020 | $149.0M |
| Q2 2020 | $149.0M |
| Q1 2020 | $171.0M |
| Q4 2019 | $152.0M |
| Q3 2019 | $193.0M |
| Q2 2019 | $137.0M |
| Q1 2019 | $214.0M |
| Q4 2018 | $150.0M |
| Q3 2018 | $157.0M |
| Q2 2018 | $183.0M |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients. A fourth quarter is the reported full year less nine months, since no filing states one.
Products (4)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| CONCERTA | METHYLPHENIDATE HYDROCHLORIDE | 36MG | TABLET, EXTENDED RELEASE;ORAL |
| CONCERTA | METHYLPHENIDATE HYDROCHLORIDE | 27MG | TABLET, EXTENDED RELEASE;ORAL |
| CONCERTA | METHYLPHENIDATE HYDROCHLORIDE | 18MG | TABLET, EXTENDED RELEASE;ORAL |
| CONCERTA | METHYLPHENIDATE HYDROCHLORIDE | 54MG | TABLET, EXTENDED RELEASE;ORAL |
4 products